Audio By Carbonatix
The Food and Drugs Authority (FDA) has reaffirmed its commitment to monitoring the safety of all vaccines used in Ghana, including COVID-19 vaccines.
The FDA says that the Emergency Use Authorization (EUA) for AstraZeneca vaccines which expired in May 2023, coincided with the World Health Organization listing COVID-19 as no longer a global public health emergency concern.
In a statement issued on Tuesday, May 21, the FDA said despite the global suspension of AstraZeneca vaccine production due to the development of new vaccines for emerging COVID-19 strains, it remains vigilant in ensuring the safety of all vaccines administered in the country.
"Despite this, the FDA remains vigilant in monitoring the safety of all vaccines used in Ghana, including COVID-19 vaccines, through its Safety Monitoring Department and its Technical Advisory Committee on Safety of Vaccines and Biological Products," part of the statement said.
The Authority said that during the pandemic, the Joint COVID-19 Vaccine Safety Review Committee (JCVSRC), established by the FDA, worked with the Ghana Health Service Expanded Programme on Immunization to oversee vaccine safety.
The FDA said that the committee also monitored global reports, including those related to Thrombosis with Thrombocytopenia Syndrome (TTS), a rare condition linked to adenoviral COVID-19 vaccines like AstraZeneca’s Vaxzevria and the Johnson & Johnson/Janssen vaccine.
"Symptoms appear between 4 and 42 days after vaccination. The estimated risk of TTS after the first dose of the AstraZeneca vaccine is about 2 per 100,000 people vaccinated, with higher rates in individuals under 60. The risk decreases after the second dose.
"As of the end of March 2024, 10,545,038 people in Ghana had received the AstraZeneca vaccine. The FDA investigated 4,149 reported adverse events following immunization (AEFIs), and thrombosis with TTS was not among them," the FDA said.
The Authority therefore assured the public of its commitment to the continuous and proactive monitoring of all regulated products to ensure they remain safe, effective, and of high quality.
"Should any product present an unacceptable risk, the FDA will take swift regulatory action to safeguard public health," the statement added.
Latest Stories
-
NAIMOS has failed in galamsey fight; it’s time for a state of emergency – DYMOG to President Mahama
1 hour -
Mahama to open African Court judicial year in Arusha, mark 20th anniversary
1 hour -
Ghana begins partial evacuation of Tehran Embassy as Middle East tensions escalate
2 hours -
EPA tightens surveillance on industries, moves to cut emissions with real-time monitoring system
2 hours -
Police conduct show of force exercise ahead of Ayawaso East by-election
4 hours -
Ghana launches revised Early Childhood Care and Development Policy to strengthen child development framework
4 hours -
AI to transform 49% of jobs in Africa within three years – PwC Survey
4 hours -
Physicist raises scientific and cost concerns over $35m EPA’s galamsey water cleaning technology
4 hours -
The road to approval: Inside Ghana’s AI strategy and KNUST’s leadership
5 hours -
Infrastructure deficit and power challenges affecting academics at AAMUSTED – SRC President
5 hours -
Former US diplomat sentenced to life for abusing two girls in Burkina Faso
5 hours -
At least 20 killed after military plane carrying banknotes crashes in Bolivia
5 hours -
UK reaffirms investment commitment at study UK Alumni Awards Ghana 2026
5 hours -
NCCE pays courtesy call on 66 Artillery Regiment, deepens stakeholder engagement Â
5 hours -
GHATOF leadership pays courtesy call on Chief of Staff, Julius Debrah
6 hours
